- Home
- APLS
as 12-20-2024 4:00pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 4.4B | IPO Year: | 2017 |
| Target Price: | $49.89 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.34 - $73.80 | Next Earning Date: | 11-05-2024 |
| Revenue: | $715,216,000 | Revenue Growth: | 162.10% |
| Revenue Growth (this year): | 95.53% | Revenue Growth (next year): | 12.94% |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Watson David O. | APLS | General Counsel | Dec 11 '24 | Sell | $34.24 | 5,000 | $171,175.00 | 112,721 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Goldman Sachs Downgrades Apellis Pharmaceuticals to Neutral From Buy, $36 Price Target
Zacks
10 days ago
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
Insider Monkey
10 days ago
Should You Hold Apellis Pharmaceuticals (APLS)?
GlobeNewswire
16 days ago
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
16 days ago
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?
Zacks
17 days ago
Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?
Simply Wall St.
18 days ago
Exploring Three High Growth Tech Stocks in the United States
GlobeNewswire
25 days ago
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.